 MELBOURNE, Australia, Aug. 17, 2021 GLOBE NEWSWIRE -- Telix Pharmaceuticals Limited ASX: TLX, Telix, the Company today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany, to conduct combination studies with one of Merck KGaA, Darmstadt, Germanys investigational proprietary DNA Damage Response Inhibitor DDRi molecules in combination with each of Telixs TLX591 177Lu-rosopatamab and TLX250 177Lu-girentuximab molecularly targeted radiation MTR therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck KGaA, Darmstadt, Germany announced in August 2019.1 